Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Pulmonary Hypertension, December 2017

Free Subscription


Abstracts

Retrieve all available abstracts of the following 73 articles:
HTML format


 

Single Articles

  1. SANTOS-MARTINEZ LE, Orihuela-Rodriguez O, Rodriguez-Almendros NA, Carmona-Ruiz H, et al
    [The pulmonary hypertension of the chronic kidney disease].
    Rev Med Inst Mex Seguro Soc. 2017;55:621-631.
    Abstract    

    Abstract available

  2. BAR N, Schwartz LA, Biner S, Aviram G, et al
    Clinical Outcome of Isolated Tricuspid Regurgitation in Patients with Preserved Left Ventricular Ejection Fraction and Pulmonary Hypertension.
    J Am Soc Echocardiogr. 2017 Nov 28. pii: S0894-7317(17)30687.
    Abstract    

    Abstract available

  3. WALLNER M, Eaton DM, Berretta RM, Borghetti G, et al
    A Feline HFpEF Model with Pulmonary Hypertension and Compromised Pulmonary Function.
    Sci Rep. 2017;7:16587.
    Abstract    

    Abstract available

  4. YOUNG KC, Bancalari E
    Should All Extremely Premature Infants Be Screened for Pulmonary Hypertension?
    Neonatology. 2017;113:89-91.
    Abstract    



  5. KARPUZ D, Giray D, Celik Y, Hallioglu O, et al
    Prognostic Markers in Congenital Diaphragmatic Hernia: Left Ventricular Diameter and Pulmonary Hypertension.
    Pediatr Int. 2017 Nov 27. doi: 10.1111/ped.13464.
    Abstract    

    Abstract available

  6. MENG X, Li Y, Li H, Lv X, et al
    Three-dimensional echocardiography to evaluate right atrial volume and phasic function in pulmonary hypertension.
    Echocardiography. 2017 Nov 26. doi: 10.1111/echo.13761.
    Abstract    

    Abstract available

  7. HELLENKAMP K, Unsold B, Mushemi-Blake S, Shah AM, et al
    Echocardiographic Estimation of Mean Pulmonary Artery Pressure: A Comparison of Different Approaches to Assign the Likelihood of Pulmonary Hypertension.
    J Am Soc Echocardiogr. 2017 Nov 23. pii: S0894-7317(17)30686.
    Abstract    

    Abstract available

  8. DI MAURO M, Foschi M, Tancredi F, Guarracini S, et al
    Additive and independent prognostic role of abnormal right ventricle and pulmonary hypertension in mitral-tricuspid surgery.
    Int J Cardiol. 2017 Nov 14. pii: S0167-5273(17)34990.
    Abstract    



  9. PONOMAREV RV, Model SV, Averbukh OM, Gavrilov AM, et al
    [Progressive pulmonary hypertension in a patient with type 1 Gaucher disease].
    Ter Arkh. 2017;89:71-74.
    Abstract    

    Abstract available

  10. PANCIERA T, Azzolin L, Cordenonsi M, Piccolo S, et al
    Mechanobiology of YAP and TAZ in physiology and disease.
    Nat Rev Mol Cell Biol. 2017;18:758-770.
    Abstract    

    Abstract available

  11. CORBOZ MR, Li Z, Malinin V, Plaunt AJ, et al
    Preclinical Pharmacology and Pharmacokinetics of Inhaled Hexadecyl-Treprostinil (C16TR), a Pulmonary Vasodilator Prodrug.
    J Pharmacol Exp Ther. 2017;363:348-357.
    Abstract    

    Abstract available

  12. SUN Z, Nie X, Sun S, Dong S, et al
    Long Non-Coding RNA MEG3 Downregulation Triggers Human Pulmonary Artery Smooth Muscle Cell Proliferation and Migration via the p53 Signaling Pathway.
    Cell Physiol Biochem. 2017;42:2569-2581.
    Abstract    

    Abstract available

  13. MALACZYNSKA-RAJPOLD K
    Response to the comment on the article entitled "Balloon atrial septostomy in pulmonary arterial hypertension: A beneficial effect on the control of rhythm abnormalities".
    Cardiol J. 2017;24:457.
    Abstract    



  14. SABINIEWICZ R
    Baloon atrial septostomy in pulmonary arterial hypertension: Atrial flow regulator - New therapeutic option.
    Cardiol J. 2017;24:455-456.
    Abstract    



  15. NEGOI RI, Ghiorghiu I, Filipoiu F, Hostiuc M, et al
    Severe pulmonary arterial hypertension associated with congenital cardiac shunts: evolution under specific treatment.
    J Med Life. 2017;10:131-138.
    Abstract    

    Abstract available

  16. SARSAM S, Kaspar G, David S, Zughaib M, et al
    Early Detection of Subclinical Aortic Valve Endocarditis with the CardioMEMS Heart Failure System.
    Am J Case Rep. 2017;18:665-668.
    Abstract    

    Abstract available

  17. SHAPIRO S, Torres F, Feldman J, Keogh A, et al
    Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic response (ATHENA-1).
    Respir Med. 2017;126:84-92.
    Abstract    

    Abstract available

  18. FERREIRA JC, Patino CM
    Types of outcomes in clinical research.
    J Bras Pneumol. 2017;43:5.
    Abstract    



  19. COSTE F, Guibert C, Magat J, Abell E, et al
    Chronic hypoxia aggravates monocrotaline-induced pulmonary arterial hypertension: a rodent relevant model to the human severe form of the disease.
    Respir Res. 2017;18:47.
    Abstract    

    Abstract available

  20. XU Y, Gu Q, Qu C
    Capsaicin pretreatment reversed pulmonary arterial hypertension by alleviating inflammation via p38MAPK pathway.
    Exp Lung Res. 2017;43:8-18.
    Abstract    

    Abstract available

  21. GALIE N, Denton CP, Dardi F, Manes A, et al
    Tadalafil in idiopathic or heritable pulmonary arterial hypertension (PAH) compared to PAH associated with connective tissue disease.
    Int J Cardiol. 2017;235:67-72.
    Abstract    

    Abstract available

  22. DUO-JI MM, Long ZW
    Comparative efficacy and acceptability of endothelin receptor antagonists for pulmonary arterial hypertension: A network meta-analysis.
    Int J Cardiol. 2017;234:90-98.
    Abstract    

    Abstract available

  23. WILD B, St-Pierre ME, Langlois S, Cowan KN, et al
    Elastase and matrix metalloproteinase activities are associated with pulmonary vascular disease in the nitrofen rat model of congenital diaphragmatic hernia.
    J Pediatr Surg. 2017 Jan 27. pii: S0022-3468(17)30042.
    Abstract    

    Abstract available

  24. ZIMMER J, Takahashi T, Hofmann AD, Puri P, et al
    Downregulation of KCNQ5 expression in the rat pulmonary vasculature of nitrofen-induced congenital diaphragmatic hernia.
    J Pediatr Surg. 2017 Jan 26. pii: S0022-3468(17)30048.
    Abstract    

    Abstract available

  25. GONZALEZ-SAIZ L, Fiuza-Luces C, Sanchis-Gomar F, Santos-Lozano A, et al
    Benefits of skeletal-muscle exercise training in pulmonary arterial hypertension: The WHOLEi+12 trial.
    Int J Cardiol. 2017;231:277-283.
    Abstract    

    Abstract available

  26. GHIO S, D'Alto M, Badagliacca R, Vitulo P, et al
    Prognostic relevance of pulmonary arterial compliance after therapy initiation or escalation in patients with pulmonary arterial hypertension.
    Int J Cardiol. 2017;230:53-58.
    Abstract    

    Abstract available

  27. JACOB SA, Novelli EM, Isenberg JS, Garrett ME, et al
    Thrombospondin-1 Gene Polymorphism is Associated with Estimated Pulmonary Artery Pressure in Patients with Sickle Cell Anemia.
    Am J Hematol. 2016 Dec 29. doi: 10.1002/ajh.24635.
    Abstract    



  28. XU T, Liu S, Ma T, Jia Z, et al
    Aldehyde dehydrogenase 2 protects against oxidative stress associated with pulmonary arterial hypertension.
    Redox Biol. 2017;11:286-296.
    Abstract    

    Abstract available

  29. FARMAKIS D, Triposkiadis F, Lekakis J, Parissis J, et al
    Heart failure in haemoglobinopathies: pathophysiology, clinical phenotypes, and management.
    Eur J Heart Fail. 2016 Dec 20. doi: 10.1002.
    Abstract    

    Abstract available

  30. MATHAI SC, Minai O, Sullivan SD, Lerner D, et al
    Rationale and study design of MOTION: A phase 4, prospective, single-arm, open-label study to measure outcomes in patients with pulmonary arterial hypertension not on active treatment.
    Respir Med. 2017;122 Suppl 1:S23-S27.
    Abstract    

    Abstract available

  31. HOEPER MM, Klinger JR, Benza RL, Simonneau G, et al
    Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors.
    Respir Med. 2017;122 Suppl 1:S18-S22.
    Abstract    

    Abstract available

  32. GRIFFIN M, Trow TK
    The evolving landscape of combination therapy for pulmonary arterial hypertension.
    Ther Adv Respir Dis. 2017;11:91-95.
    Abstract    

    Abstract available

  33. HOEPER MM, McLaughlin VV, Barbera JA, Frost AE, et al
    Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study.
    Lancet Respir Med. 2016;4:894-901.
    Abstract    

    Abstract available

  34. DISTLER O, Pope J, Denton C, Allanore Y, et al
    RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis.
    Respir Med. 2017;122 Suppl 1:S14-S17.
    Abstract    

    Abstract available

  35. HAHN SS, Makaryus M, Talwar A, Narasimhan M, et al
    A review of therapeutic agents for the management of pulmonary arterial hypertension.
    Ther Adv Respir Dis. 2017;11:46-63.
    Abstract    

    Abstract available

  36. BURGOS CM, Pearson EG, Davey M, Riley J, et al
    Improved pulmonary function in the nitrofen model of congenital diaphragmatic hernia following prenatal maternal dexamethasone and/or sildenafil.
    Pediatr Res. 2016 Jul 4. doi: 10.1038/pr.2016.
    Abstract    

    Abstract available

  37. EDAHIRO Y, Takaku T, Konishi H, Tsukune Y, et al
    [Chronic myeloid leukemia complicated by pulmonary hypertension during dasatinib therapy: a single-center retrospective study].
    Rinsho Ketsueki. 2017;58:2213-2218.
    Abstract    

    Abstract available

  38. CHRISTOU H, Hudalla H, Michael Z, Filatava E, et al
    Impaired Pulmonary Arterial Vasoconstriction and Nitric Oxide-Mediated Relaxation Underlie Severe Pulmonary Hypertension in Sugen-Hypoxia Rat Model.
    J Pharmacol Exp Ther. 2017 Dec 6. pii: jpet.117.244798.
    Abstract    

    Abstract available

  39. BERGHAUS TM, Kutsch J, Faul C, von Scheidt W, et al
    The association of N-terminal pro-brain-type natriuretic peptide with hemodynamics and functional capacity in therapy-naive precapillary pulmonary hypertension: results from a cohort study.
    BMC Pulm Med. 2017;17:167.
    Abstract    

    Abstract available

  40. WANG L, Jin YZ, Zhao QH, Jiang R, et al
    Hemodynamic and gas exchange effects of inhaled iloprost in patients with COPD and pulmonary hypertension.
    Int J Chron Obstruct Pulmon Dis. 2017;12:3353-3360.
    Abstract    

    Abstract available

  41. COONS JC, Bunner C, Ishizawar DC, Risbano MG, et al
    Impact of four times daily dosing of oral treprostinil on tolerability and daily dose achieved in pulmonary hypertension.
    Pulm Circ. 2018;8:2045893217744512.
    Abstract    

    Abstract available

  42. WARRICKER F, Islam Z, Shah BN
    Lesson of the month 1: Obesity hypoventilation (Pickwickian) syndrome: a reversible cause of severe pulmonary hypertension.
    Clin Med (Lond). 2017;17:578-581.
    Abstract    

    Abstract available

  43. CONNOLLY MJ, Abdullah S, Ridout DA, Schreiber BE, et al
    Prognostic significance of computed tomography criteria for pulmonary veno-occlusive disease in systemic sclerosis-pulmonary arterial hypertension.
    Rheumatology (Oxford). 2017;56:2197-2203.
    Abstract    

    Abstract available

  44. VALIEVA ZS, Martynyuk TV, Chazova IE
    [Bosentan use in pulmonary arterial hypertension: Russian and foreign experience].
    Ter Arkh. 2017;89:95-103.
    Abstract    

    Abstract available

  45. KING CS, Roy A, Ryan L, Singh R, et al
    Cardiac Support: Emphasis on Venoarterial ECMO.
    Crit Care Clin. 2017;33:777-794.
    Abstract    

    Abstract available

  46. ALVAREZ RA, Miller MP, Hahn SA, Galley JC, et al
    Targeting Pulmonary Endothelial Hemoglobin alpha Improves Nitric Oxide Signaling and Reverses Pulmonary Artery Endothelial Dysfunction.
    Am J Respir Cell Mol Biol. 2017;57:733-744.
    Abstract    

    Abstract available

  47. GORBACHEVSKY SV, Shmalts AA, Barishnikova IY, Zaets SB, et al
    Potts shunt in children with pulmonary arterial hypertension: institutional experience.
    Interact Cardiovasc Thorac Surg. 2017;25:595-599.
    Abstract    

    Abstract available

  48. PENA A, Kobir A, Goncharov D, Goda A, et al
    Pharmacological Inhibition of mTOR Kinase Reverses Right Ventricle Remodeling and Improves Right Ventricle Structure and Function in Rats.
    Am J Respir Cell Mol Biol. 2017;57:615-625.
    Abstract    

    Abstract available

  49. KOJONAZAROV B, Novoyatleva T, Boehm M, Happe C, et al
    p38 MAPK Inhibition Improves Heart Function in Pressure-Loaded Right Ventricular Hypertrophy.
    Am J Respir Cell Mol Biol. 2017;57:603-614.
    Abstract    

    Abstract available

  50. SANKHE S, Manousakidi S, Antigny F, Arthur Ataam J, et al
    T-type Ca(2+) channels elicit pro-proliferative and anti-apoptotic responses through impaired PP2A/Akt1 signaling in PASMCs from patients with pulmonary arterial hypertension.
    Biochim Biophys Acta. 2017;1864:1631-1641.
    Abstract    

    Abstract available

  51. AXELL RG, Messer SJ, White PA, McCabe C, et al
    Ventriculo-arterial coupling detects occult RV dysfunction in chronic thromboembolic pulmonary vascular disease.
    Physiol Rep. 2017;5.
    Abstract    

    Abstract available

  52. LUITEL H, Sydykov A, Schymura Y, Mamazhakypov A, et al
    Pressure overload leads to an increased accumulation and activity of mast cells in the right ventricle.
    Physiol Rep. 2017;5.
    Abstract    

    Abstract available

  53. ROL N, Timmer EM, Faes TJ, Vonk Noordegraaf A, et al
    Vascular narrowing in pulmonary arterial hypertension is heterogeneous: rethinking resistance.
    Physiol Rep. 2017;5.
    Abstract    

    Abstract available

  54. SCHEY C, Krabbe PF, Postma MJ, Connolly MP, et al
    Multi-criteria decision analysis (MCDA): testing a proposed MCDA framework for orphan drugs.
    Orphanet J Rare Dis. 2017;12:10.
    Abstract    

    Abstract available

  55. MONTANI D, Girerd B, Jais X, Levy M, et al
    Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study.
    Lancet Respir Med. 2017;5:125-134.
    Abstract    

    Abstract available

  56. HUMMLER JK, Dapaah-Siakwan F, Vaidya R, Zambrano R, et al
    Inhibition of Rac1 Signaling Downregulates Inflammasome Activation and Attenuates Lung Injury in Neonatal Rats Exposed to Hyperoxia.
    Neonatology. 2017;111:280-288.
    Abstract    

    Abstract available

  57. ONG SB, Hausenloy DJ
    Mitochondrial Dynamics as a Therapeutic Target for Treating Cardiac Diseases.
    Handb Exp Pharmacol. 2017;240:251-279.
    Abstract    

    Abstract available

  58. KING CS, Nathan SD
    Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities.
    Lancet Respir Med. 2017;5:72-84.
    Abstract    

    Abstract available

  59. GHOFRANI HA, Grimminger F, Grunig E, Huang Y, et al
    Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial.
    Lancet Respir Med. 2016 Apr 8. pii: S2213-2600(16)30019.
    Abstract    

    Abstract available

  60. PLOEGSTRA MJ, Ivy DD, Wheeler JG, Brand M, et al
    Growth in children with pulmonary arterial hypertension: a longitudinal retrospective multiregistry study.
    Lancet Respir Med. 2016 Mar 16. pii: S2213-2600(16)00069.
    Abstract    

    Abstract available

  61. LAJOIE AC, Lauziere G, Lega JC, Lacasse Y, et al
    Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis.
    Lancet Respir Med. 2016 Feb 26. pii: S2213-2600(16)00027.
    Abstract    

    Abstract available

  62. TANNENBERG P, Chang YT, Muhl L, Lavina B, et al
    Extracellular Retention of PDGF-B Directs Vascular Remodeling in Mouse Hypoxia-induced Pulmonary Hypertension.
    Am J Physiol Lung Cell Mol Physiol. 2017 Dec 6:ajplung.00054.2017.
    Abstract    

    Abstract available

  63. KATO F, Sakao S, Takeuchi T, Suzuki T, et al
    Endothelial cell-related autophagic pathways in Sugen/hypoxia-exposed pulmonary arterial hypertensive rats.
    Am J Physiol Lung Cell Mol Physiol. 2017;313:L899-L915.
    Abstract    

    Abstract available

  64. YUN X, Jiang H, Lai N, Wang J, et al
    Aquaporin 1-mediated changes in pulmonary arterial smooth muscle cell migration and proliferation involve beta-catenin.
    Am J Physiol Lung Cell Mol Physiol. 2017;313:L889-L898.
    Abstract    

    Abstract available

  65. MARON BA, Wertheim BM, Gladwin MT
    Under Pressure to Clarify Pulmonary Hypertension Clinical Risk.
    Am J Respir Crit Care Med. 2017 Dec 7. doi: 10.1164/rccm.201711-2306.
    Abstract    



  66. HADINNAPOLA C, Bleda M, Haimel M, Screaton N, et al
    Phenotypic Characterisation of EIF2AK4 Mutation Carriers in a Large Cohort of Patients Diagnosed Clinically with Pulmonary Arterial Hypertension.
    Circulation. 2017 Sep 28. pii: CIRCULATIONAHA.117.028351.
    Abstract    

    Abstract available

  67. SAITO T, Miyagawa K, Chen SY, Tamosiuniene R, et al
    Upregulation of HERV-K is Linked to Immunity and Inflammation in Pulmonary Arterial Hypertension.
    Circulation. 2017 Sep 21. pii: CIRCULATIONAHA.117.027589.
    Abstract    

    Abstract available

  68. RAMADAN ME, Shabsigh M, Awad H
    Con: Inhaled Pulmonary Vasodilators Are Not Indicated in Patients Undergoing Lung Transplantation.
    J Cardiothorac Vasc Anesth. 2016 Aug 31. pii: S1053-0770(16)30374.
    Abstract    



  69. CAMPOS C, Luz de Castro A, Vicente Tavares AM, Fernandes RO, et al
    Effect of free and nanoencapsulated copaiba oil on monocrotaline-induced pulmonary arterial hypertension.
    J Cardiovasc Pharmacol. 2016.
    Abstract    

    Abstract available

  70. SURESH G, King BC, Jain SK
    Screening for pulmonary hypertension in preterm infants-not ready for prime time.
    J Perinatol. 2017 Nov 27. pii: 10.1038/s41372-017-0014.
    Abstract    



  71. PRICE LC, Dimopoulos K, Marino P, Alonso-Gonzalez R, et al
    The CRASH report: emergency management dilemmas facing acute physicians in patients with pulmonary arterial hypertension.
    Thorax. 2017;72:1035-1045.
    Abstract    

    Abstract available

  72. GHIO S, Crimi G, Pica S, Temporelli PL, et al
    Persistent abnormalities in pulmonary arterial compliance after heart transplantation in patients with combined post-capillary and pre-capillary pulmonary hypertension.
    PLoS One. 2017;12:e0188383.
    Abstract    

    Abstract available

  73. LOPEZ-MESEGUER M, Quezada CA, Ramon MA, Lazaro M, et al
    Lung and heart-lung transplantation in pulmonary arterial hypertension.
    PLoS One. 2017;12:e0187811.
    Abstract    

    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Pulmonary Hypertension is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design:


;